JP2022544702A5 - - Google Patents

Info

Publication number
JP2022544702A5
JP2022544702A5 JP2022511203A JP2022511203A JP2022544702A5 JP 2022544702 A5 JP2022544702 A5 JP 2022544702A5 JP 2022511203 A JP2022511203 A JP 2022511203A JP 2022511203 A JP2022511203 A JP 2022511203A JP 2022544702 A5 JP2022544702 A5 JP 2022544702A5
Authority
JP
Japan
Prior art keywords
approximately
premrna
composition according
exon
canonical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022511203A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544702A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/047081 external-priority patent/WO2021034985A1/en
Publication of JP2022544702A publication Critical patent/JP2022544702A/ja
Publication of JP2022544702A5 publication Critical patent/JP2022544702A5/ja
Pending legal-status Critical Current

Links

JP2022511203A 2019-08-19 2020-08-19 スプライシングおよびタンパク質発現を調節するための組成物および方法 Pending JP2022544702A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962888887P 2019-08-19 2019-08-19
US62/888,887 2019-08-19
US202063049262P 2020-07-08 2020-07-08
US63/049,262 2020-07-08
PCT/US2020/047081 WO2021034985A1 (en) 2019-08-19 2020-08-19 Compositions and methods for modulating splicing and protein expression

Publications (2)

Publication Number Publication Date
JP2022544702A JP2022544702A (ja) 2022-10-20
JP2022544702A5 true JP2022544702A5 (enExample) 2023-08-28

Family

ID=74659533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022511203A Pending JP2022544702A (ja) 2019-08-19 2020-08-19 スプライシングおよびタンパク質発現を調節するための組成物および方法

Country Status (11)

Country Link
US (1) US20220290142A1 (enExample)
EP (1) EP4017979A4 (enExample)
JP (1) JP2022544702A (enExample)
KR (1) KR20220104677A (enExample)
CN (1) CN114746550A (enExample)
AU (1) AU2020334067A1 (enExample)
BR (1) BR112022002905A2 (enExample)
CA (1) CA3147970A1 (enExample)
IL (1) IL290595A (enExample)
MX (1) MX2022002198A (enExample)
WO (1) WO2021034985A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7652713B2 (ja) * 2019-05-27 2025-03-27 ビジョン ファーマ ピーティーワイ リミテッド 新規の網膜色素変性処置
KR20220054401A (ko) * 2019-09-03 2022-05-02 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 감염의 숙주 rna 바이오마커의 신속한 조기-검출 및 인간의 covid-19 코로나바이러스 감염의 조기 식별을 위한 시스템, 방법 및 조성물
CN115916977A (zh) * 2020-05-11 2023-04-04 弗洛里神经科学与心理健康研究所 用于治疗与syngap1中功能失去突变相关的障碍的组合物和方法
CN117980479A (zh) * 2021-06-21 2024-05-03 斯托克制药公司 用于治疗基于无义介导的rna衰变的病状和疾病的反义寡聚体
WO2023004021A2 (en) * 2021-07-23 2023-01-26 The Children's Medical Center Corporation Zinc finger ccch-type containing 14 (zc3h14) mutants and methods of use
WO2023163801A1 (en) * 2022-02-24 2023-08-31 Q-State Biosciences, Inc. Therapeutics for syngap haploinsufficiency
EP4504951A2 (en) * 2022-04-05 2025-02-12 The Johns Hopkins University Methods and materials for treating syngap1-associated neurodevelopmental disorders
WO2023212625A1 (en) * 2022-04-28 2023-11-02 AcuraStem Incorporated Syf2 antisense oligonucleotides
US20250313832A1 (en) * 2022-05-13 2025-10-09 The Trustees Of The University Of Pennsylvania Compositions for treating syngap-1 related neurodevelopmental disorders
US20250368991A1 (en) * 2022-06-28 2025-12-04 Agency For Science, Technology And Research Oligonucleotides
WO2025090633A1 (en) * 2023-10-23 2025-05-01 Regeneron Pharmaceuticals, Inc. Compositions and methods comprising small nuclear rna (snrna) for treating genetic epilepsies
WO2025111249A2 (en) * 2023-11-20 2025-05-30 Dana-Farber Cancer Institute, Inc. Methods, kits and systems for determining sarcomatoid differentiation of renal cell carcinoma and methods for treating based on the same
GB202401412D0 (en) * 2024-02-02 2024-03-20 Harness Therapeutics Ltd Functional nucleic acid

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009064920A2 (en) * 2007-11-13 2009-05-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating protein expression
EP2364325A4 (en) * 2008-11-07 2012-07-25 Ct Hospitalier Universitaire Sainte Justine SYNGAP1 DYSFUNCTIONS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS FOR INTELLECTUAL SENTENCING
AU2015327836B2 (en) * 2014-10-03 2021-07-01 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
CN108603230A (zh) * 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
WO2017106377A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
EP3390666A4 (en) * 2015-12-14 2019-08-07 Cold Spring Harbor Laboratory COMPOSITIONS AND METHODS OF TREATING NURSE DISEASES
EP3390635A4 (en) * 2015-12-14 2019-05-01 Cold Spring Harbor Laboratory Antisense oligomers for the treatment of a tuberous sclerosis complex
JP2019500345A (ja) * 2015-12-14 2019-01-10 コールド スプリング ハーバー ラボラトリー 肝臓病の処置のための組成物および方法
JP2018538287A (ja) * 2015-12-14 2018-12-27 コールド スプリング ハーバー ラボラトリー 多発性嚢胞腎の処置のためのアンチセンスオリゴマー
JP7036723B2 (ja) * 2015-12-14 2022-03-15 コールド スプリング ハーバー ラボラトリー 眼疾患の処置のための組成物および方法
EA201991309A1 (ru) * 2016-11-28 2019-11-29 Способы модуляции сплайсинга рнк
KR102318434B1 (ko) * 2017-08-25 2021-11-01 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
HUE070436T2 (hu) * 2017-10-23 2025-06-28 Stoke Therapeutics Inc Antiszensz oligomerek nonszensz-mediált RNS-lebomláson alapuló állapotok és betegségek kezelésére

Similar Documents

Publication Publication Date Title
JP2022544702A5 (enExample)
ES2692886T3 (es) Métodos y medios para el salto eficaz de al menos uno de los siguientes exones del gen de distrofia muscular de Duchenne humana: 43, 46, 50-53
ES2551154T3 (es) Procedimiento para la eficiente omisión del exón (44) en distrofia muscular de Duchenne y medios asociados
US20220090088A1 (en) Targeted Nuclear RNA Cleavage and Polyadenylation with CRISPR-Cas
US20210395754A1 (en) Splice-switching oligonucleotides and methods of use
JP6791877B2 (ja) デュシェンヌ型筋ジストロフィーを治療するためのダイナミン２阻害剤
TWI899403B (zh) Rna治療劑及其使用方法
US20230235298A1 (en) Phenylalanine hydroxylase variants and uses thereof
EP3177313B1 (en) Telomerase reverse transcriptase-based therapies for treatment of conditions associated with myocardial infarction
JP7664233B2 (ja) 治療
JP2018519250A (ja) 治療薬としてのｓｍａｄ７遺伝子送達
CN120775846A (zh) 反义寡核苷酸及其在疼痛治疗中的应用
CA3125310A1 (en) Double stranded rna and uses thereof
JP2024507717A5 (enExample)
CN119233981A (zh) 用于组织特异性表达的启动子开关
EP4366785A1 (en) Treatment for tyrosine degradation-associated disorders
CN116490216A (zh) Sarna和mrna调节剂联合治疗sma
US20250345462A1 (en) Compositions and methods for treating liver disease
WO2025147949A1 (zh) 基因编辑系统及其应用
US20230078498A1 (en) Targeted Translation of RNA with CRISPR-Cas13 to Enhance Protein Synthesis
WO2025253282A1 (en) Small interfering nucletides (sioligo) for the treatment of cole-carpenter syndrome (ccs)
WO2026009728A1 (ja) アンチセンス核酸及びその使用
KR101888104B1 (ko) MET 엑손 14 스키핑 특이적 siRNA 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물
JP2025084707A (ja) アンチセンス核酸およびその利用
WO2021085592A1 (ja) 疾患特異的なｃｏｌ３ａ１変異アレルの遺伝子発現を抑制する核酸および血管型エーラス・ダンロス症候群を処置するための医薬組成物